European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,700 shares, an increase of 240.0% from the August 15th total of 500 shares. Based on an average trading volume of 16,200 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.
European Biotech Acquisition Stock Performance
EBAC stock remained flat at $9.88 during trading on Friday. The company had a trading volume of 610 shares, compared to its average volume of 28,695. European Biotech Acquisition has a fifty-two week low of $9.66 and a fifty-two week high of $10.50. The business has a fifty day moving average price of $9.86.
Get European Biotech Acquisition alerts:Hedge Funds Weigh In On European Biotech Acquisition
A hedge fund recently raised its stake in European Biotech Acquisition stock. Cubist Systematic Strategies LLC boosted its holdings in shares of European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) by 136.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,555 shares of the company's stock after purchasing an additional 34,896 shares during the period. Cubist Systematic Strategies LLC's holdings in European Biotech Acquisition were worth $593,000 as of its most recent SEC filing.
About European Biotech Acquisition
(Get Rating)European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Read More
- Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.